CAR Traffic jam: who can use the fast lane?

Despite the promising results of chimeric antigen receptor (CAR) T-cell therapies in patients with acute lymphoblastic leukemia, lymphoma, and multiple myeloma (MM), not all eligible patients have the opportunity to benefit from this treatment, due to long waiting lists and (inter)national variation in availability of this therapy. In this issue of Blood, Bell et al discuss a framework to help make difficult decisions in prioritizing patients receiving CAR T-cell therapy when limited CAR T-cell production slots are available.(1)

Automated summary

Despite the promising results of CAR T-cell therapies in certain types of cancer, limited production slots and variations in availability have prevented all eligible patients from benefiting. A framework for prioritizing patients receiving CAR T-cell therapy is discussed in this study.